Trials / Available
AvailableNCT06743776
Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Mayo Clinic · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this Expanded Access Program is to provide MN-166 (ibudilast) to ALS patients who are not eligible for an enrolling ALS clinical trial. This Expanded Access Program will assess if MN-166 can help people with ALS in slowing down the progression of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MN-166 | MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken. |
Timeline
- First posted
- 2024-12-20
- Last updated
- 2026-03-12
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT06743776. Inclusion in this directory is not an endorsement.